Telmisartan – hypertension

 

1. Mechanism of Action

• Class: Angiotensin II Receptor Blocker (ARB)

• Action: Blocks AT₁ receptors → inhibits angiotensin II-induced:

  • Vasoconstriction

  • Aldosterone secretion

  • Cardiac remodeling

• Unique Feature: Partial PPAR-γ agonist → improves insulin sensitivity & lipid metabolism.

---

2. FDA-Approved Uses

Indication	Dosage	Key Benefit
Hypertension (HTN)	40-80 mg once daily	24-hour BP control
CV Risk Reduction	80 mg once daily	↓ Stroke/MI in high-risk patients

---

3. Dosing & Administration

• Starting Dose: 40 mg daily

• Target Dose: 80 mg daily (max)

• Take: With/without food, same time daily

• Titration: Adjust monthly (full effect in 4-8 weeks)

• Special Populations:

  • Elderly/Renal/Liver Impairment: Max 40 mg/day

---

4. Key Advantages

Feature	Clinical Impact
24-hour half-life	Superior nocturnal BP control
PPAR-γ agonism	↓ Triglycerides, ↑ HDL-C
Tissue penetration	Protects heart/kidneys
No cough (vs. ACEi)	Better adherence

💡 Preferred for HTN + metabolic syndrome/diabetes

---

5. Critical Warnings

• 🚫 Pregnancy (Category D): Discontinue immediately if pregnant → risk of fetal injury.

• Hyperkalemia: Monitor K⁺ (baseline, 1-2 weeks, quarterly).

• Renal Artery Stenosis: Avoid in bilateral stenosis.

• Angioedema: Rare but possible (emergency treatment needed).

---

6. Drug Interactions

Interacting Drug	Risk	Management
NSAIDs (e.g., ibuprofen)	↑ AKI/hyperkalemia	Avoid or monitor K⁺/creatinine
Aliskiren	↑ Renal toxicity	Contraindicated in diabetes
Lithium	↑ Lithium toxicity	Avoid combo

---

7. Side Effects

Common (≥5%)	Serious (<1%)
Dizziness	Hyperkalemia (K⁺ >5.5 mEq/L)
Back pain	Acute kidney injury
Sinusitis	Hepatotoxicity (rare)

---

8. Cardiovascular Protection

• Stroke Reduction: 23% (PRoFESS Trial)

• MI Reduction: 13% (ONTARGET Substudy)

• Use: ACEi-intolerant patients with:

  • Coronary artery disease

  • Diabetes

  • Left ventricular hypertrophy

---

9. Monitoring & Safety

• Baseline: K⁺, creatinine, LFTs

• BP Checks: Weekly self-monitoring

• Renal Function: Recheck 1-2 weeks after starting

• Avoid in: Volume depletion, severe heart failure

---

10. Patient Counseling

1. "Do NOT stop suddenly – BP will rise gradually."

2. "Report: Swelling (face/lips), muscle weakness, dark urine."

3. "Avoid NSAIDs – use acetaminophen for pain."

4. "Use contraception – stop drug if planning pregnancy."

5. "Check BP at home – log AM/PM readings."

---

🆚 Telmisartan vs. Other ARBs

Parameter	Telmisartan	Losartan
Half-life	24 hours	6-9 hours
Metabolic Effects	PPAR-γ agonist	Neutral
Dosing	Once daily	Once daily
Cost (generic)	~$0.50/dose	~$0.10/dose

Prescribing Tip: First-line for HTN with diabetes/metabolic syndrome (per ADA/ESC guidelines).

⚠️ Red Flag: Combining with ACE inhibitors (e.g., lisinopril) increases renal risk → avoid dual RAS blockade.

Sources: ADA Standards of Care (2024), ESC Guidelines (2023), ONTARGET Trial (NEJM).